ALDVI — Advicenne SA Share News
0.000.00%
Last trade - 00:00- €15.83m
- €33.49m
- €6.01m
Brief: Advicenne Expects Imminent Marketing Authorization For ADV7103 (Sibnayal™) For dRTA In Europe
Brief: Advicenne Updates On Clinical Program In Cystinuria In EU
Brief: Advicenne Appoints Peter Meeus As CEO
Brief: Advicenne Receives Positive CHMP Opinion Recommending Approval Of ADV7103 (Sibnayal®)
Brief: French pharmaceutical company Advicenne gets 4.3 mln euros loan, backed by French government
Brief: Advicenne Announces The Drawdown Of A First Tranche Of 7.5 Million Euros
Brief: Advicenne Updates On ADV7103
Brief: Advicenne FY Net Loss Widens To 14.2 Million Euros
Brief: Advicienne Appoints Andre Ulmann Interim CEO
Brief: Advicenne Says EMA Granted ADV7103 Orphan Drug Designation
Brief: Advicenne To Appoint David Horn Solomon As Chairman Of The Board
Brief: Advicenne SA Presented Additional Efficacy Data On Adv7103
Brief: Advicenne H1 Net Loss Widens to EUR 6.8 Million
Brief: Advicenne Signs Agreement With Elaiapharm Lundbeck For Manufacturing Of ADV7103
Brief: Advicenne: 1st Patient Enrolled In US ARENA-2 Pivotal Phase III Clinical Trial Evaluating ADV7103 In dRTA
Brief: Advicenne Signs 20 Million Euros Financing Agreement With European Investment Bank
Brief: Advicenne Announces Successful Listing Of Its Shares On Euronext Brussels
Brief: Advicenne To List On Regulated Market Of Euronext Brussels
Brief: Advicenne FY Operating Loss Narrows To 5.3 Million Euros